Sergi Betriu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sergi Betriu has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Jordi Rovira
Nephrology and Transplantation (LENIT), Fundació Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain
2 shared publications - Sebastiaan Heidt
Department of Internal Medicine, Erasmus MC Transplant Institute, Erasmus Medical Center
2 shared publications - Aiko P. J. de Vries
Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands
1 shared publication - Ainhoa García-Busquets
Laboratori Experimental de Nefrologia I Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
1 shared publication Ainhoa García‐Busquets
Laboratori Experimental de Nefrologia i Trasplantament (LENIT) Fundació de Recerca Clinic Barcelona‐Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB‐IDIBAPS) Barcelona Spain
1 shared publicationArend Mulder
Department of Immunology Leiden University Medical Center Leiden The Netherlands
1 shared publication
Latest Publications
- Open Access
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Chimeric HLA Antibody Receptor T Cells to Specifically Eliminate HLA-DQ–Specific B Cells
Key Points: HLA-DQ2/DQ7 chimeric HLA antibody receptor T cells, the first HLA class II chimeric HLA antibody receptor T cells, selectively eliminated cognate HLA-DQ–specific B cells in a dose-dependent manner. HLA-DQ chimeric HLA antibody receptor T cells efficiently depleted HLA-DQ–specific B cells with corresponding specificity in vivo . Chimeric HLA antibody receptor T-cell therapy expanded donor availability through targeted desensitization and represented a potential antigen-specific antibody-mediated rejection therapy. Background: Chimeric antigen receptor T-cell therapy has revolutionized the treatment of hematologic malignancies by effectively eliminating tumor cells. In the field of kidney transplantation, comparable cellular therapies are being explored to facilitate transplantation and prevent graft rejection. Chimeric HLA antibody receptor (CHAR) T cells are a promising therapy for eliminating HLA-specific B cells in sensitized patients and potentially ameliorating antibody-mediated rejection. We previously demonstrated that HLA class I CHAR T cells selectively eliminated HLA class I–specific B cells with high specificity. Since HLA sensitization is most often directed against HLA-DQ of the allograft, we developed HLA-DQ2 and HLA-DQ7 CHAR T cells to target B cells with corresponding HLA specificity. Methods: We designed viral vectors encoding HLA-DQ CHARs composed of HLA-DQA1*05:01 α chain with either HLA-DQB1*02:01 (HLA-DQ2) or HLA-DQB1*03:01 (HLA-DQ7) β chains, class II–associated invariant chain peptide, and intracellular 4-1BB costimulatory and CD3ζ signaling domains. Upon production of HLA-DQ CHAR T cells, we evaluated CHAR expression, cytotoxic activity, production of cytokines and cytotoxic mediators, and sensitivity to immunosuppressive drugs in in vitro models. We further assessed the cytotoxic activity of HLA-DQ CHAR T cells in an immunodeficient mouse model and in primary material from sensitized individuals. Results: CHAR-transduced Jurkat triple parameter reporter cells expressing reporter constructs for T-cell activation markers showed robust activation upon specific stimulation. Primary CD8 + T cells expressing HLA-DQ2 and HLA-DQ7 CHAR molecules specifically eliminated HLA-DQ2– or HLA-DQ7–specific B cells, respectively, and produced interferon gamma, soluble Fas ligand, perforin, and granzyme B. Maintenance immunosuppressive drug regimens initiated at the time of coincubation with target cells had limited effects on CHAR T-cell functionality. Finally, HLA-DQ CHAR T cells effectively eliminated HLA-DQ–specific B cells in an in vivo mouse model, as well as in primary material from sensitized individuals. Conclusions: HLA-DQ2 and HLA-DQ7 CHAR T cells, the first HLA class II CHAR T cells, selectively and effectively eliminated corresponding HLA-DQ–specific B cells in vitro , in vivo , and in primary material from sensitized individuals.
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Open AccessChimeric HLA Antibody Receptor T Cells to Specifically Eliminate HLA-DQ–Specific B Cells
Key Points: HLA-DQ2/DQ7 chimeric HLA antibody receptor T cells, the first HLA class II chimeric HLA antibody receptor T cells, selectively eliminated cognate HLA-DQ–specific B cells in a dose-dependent manner. HLA-DQ chimeric HLA antibody receptor T cells efficiently depleted HLA-DQ–specific B cells with corresponding specificity in vivo . Chimeric HLA antibody receptor T-cell therapy expanded donor availability through targeted desensitization and represented a potential antigen-specific antibody-mediated rejection therapy. Background: Chimeric antigen receptor T-cell therapy has revolutionized the treatment of hematologic malignancies by effectively eliminating tumor cells. In the field of kidney transplantation, comparable cellular therapies are being explored to facilitate transplantation and prevent graft rejection. Chimeric HLA antibody receptor (CHAR) T cells are a promising therapy for eliminating HLA-specific B cells in sensitized patients and potentially ameliorating antibody-mediated rejection. We previously demonstrated that HLA class I CHAR T cells selectively eliminated HLA class I–specific B cells with high specificity. Since HLA sensitization is most often directed against HLA-DQ of the allograft, we developed HLA-DQ2 and HLA-DQ7 CHAR T cells to target B cells with corresponding HLA specificity. Methods: We designed viral vectors encoding HLA-DQ CHARs composed of HLA-DQA1*05:01 α chain with either HLA-DQB1*02:01 (HLA-DQ2) or HLA-DQB1*03:01 (HLA-DQ7) β chains, class II–associated invariant chain peptide, and intracellular 4-1BB costimulatory and CD3ζ signaling domains. Upon production of HLA-DQ CHAR T cells, we evaluated CHAR expression, cytotoxic activity, production of cytokines and cytotoxic mediators, and sensitivity to immunosuppressive drugs in in vitro models. We further assessed the cytotoxic activity of HLA-DQ CHAR T cells in an immunodeficient mouse model and in primary material from sensitized individuals. Results: CHAR-transduced Jurkat triple parameter reporter cells expressing reporter constructs for T-cell activation markers showed robust activation upon specific stimulation. Primary CD8 + T cells expressing HLA-DQ2 and HLA-DQ7 CHAR molecules specifically eliminated HLA-DQ2– or HLA-DQ7–specific B cells, respectively, and produced interferon gamma, soluble Fas ligand, perforin, and granzyme B. Maintenance immunosuppressive drug regimens initiated at the time of coincubation with target cells had limited effects on CHAR T-cell functionality. Finally, HLA-DQ CHAR T cells effectively eliminated HLA-DQ–specific B cells in an in vivo mouse model, as well as in primary material from sensitized individuals. Conclusions: HLA-DQ2 and HLA-DQ7 CHAR T cells, the first HLA class II CHAR T cells, selectively and effectively eliminated corresponding HLA-DQ–specific B cells in vitro , in vivo , and in primary material from sensitized individuals.
- Open Access
Chimeric HLA antibody receptor T cells for targeted therapy of antibody‐mediated rejection in transplantation
The presence of donor‐specific antibodies (DSA), mainly against HLA, increases the risk of allograft rejection. Moreover, antibody‐mediated rejection (ABMR) remains an important barrier to optimal long‐term outcomes after solid organ transplantation. The development of chimeric autoantibody receptor T lymphocytes has been postulated for targeted therapy of autoimmune diseases. We aimed to develop a targeted therapy for DSA desensitization and ABMR, generating T cells with a chimeric HLA antibody receptor (CHAR) that specifically eliminates DSA‐producing B cells. We have genetically engineered an HLA‐A2‐specific CHAR (A2‐CHAR) and transduced it into human T cells. Then, we have performed in vitro experiments such as cytokine measurement, effector cell activation, and cytotoxicity against anti‐HLA‐A2 antibody‐expressing target cells. In addition, we have performed A2‐CHAR‐Tc cytotoxic assays in an immunodeficient mouse model. A2‐CHAR expressing T cells could selectively eliminate HLA‐A2 antibody‐producing B cells in vitro. The cytotoxic capacity of A2‐CHAR expressing T cells mainly depended on Granzyme B release. In the NSG mouse model, A2‐CHAR‐T cells could identify and eradicate HLA‐A2 antibody‐producing B cells even when those cells are localized in the bone marrow. This ability is effector:target ratio dependent. CHAR technology generates potent and functional human cytotoxic T cells to target alloreactive HLA class I antibody‐producing B cells. Thus, we consider that CHAR technology may be used as a selective desensitization protocol or an ABMR therapy in transplantation.
Open AccessChimeric HLA antibody receptor T cells for targeted therapy of antibody‐mediated rejection in transplantation
The presence of donor‐specific antibodies (DSA), mainly against HLA, increases the risk of allograft rejection. Moreover, antibody‐mediated rejection (ABMR) remains an important barrier to optimal long‐term outcomes after solid organ transplantation. The development of chimeric autoantibody receptor T lymphocytes has been postulated for targeted therapy of autoimmune diseases. We aimed to develop a targeted therapy for DSA desensitization and ABMR, generating T cells with a chimeric HLA antibody receptor (CHAR) that specifically eliminates DSA‐producing B cells. We have genetically engineered an HLA‐A2‐specific CHAR (A2‐CHAR) and transduced it into human T cells. Then, we have performed in vitro experiments such as cytokine measurement, effector cell activation, and cytotoxicity against anti‐HLA‐A2 antibody‐expressing target cells. In addition, we have performed A2‐CHAR‐Tc cytotoxic assays in an immunodeficient mouse model. A2‐CHAR expressing T cells could selectively eliminate HLA‐A2 antibody‐producing B cells in vitro. The cytotoxic capacity of A2‐CHAR expressing T cells mainly depended on Granzyme B release. In the NSG mouse model, A2‐CHAR‐T cells could identify and eradicate HLA‐A2 antibody‐producing B cells even when those cells are localized in the bone marrow. This ability is effector:target ratio dependent. CHAR technology generates potent and functional human cytotoxic T cells to target alloreactive HLA class I antibody‐producing B cells. Thus, we consider that CHAR technology may be used as a selective desensitization protocol or an ABMR therapy in transplantation.